• 1. Establishing new scaling relations on two-dimensional MXenes for CO2 electroreduction?
  Albertus D. Handoko,Khoong Hong Khoo,Teck Leong Tan,Hongmei Jin,Zhi Wei Seh J. Mater. Chem. A, 2018,6, 21885-21890
• 2. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860
• 3. Emulsion technologies for multicellular tumour spheroid radiation assays?
  Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
• 4. Establishing plasmon contribution to chemical reactions: alkoxyamines as a thermal probe?
  Olga Guselnikova,Gérard Audran,Jean-Patrick Joly,Andrii Trelin,Evgeny V. Tretyakov,Vaclav Svorcik,Oleksiy Lyutakov,Sylvain R. A. Marque Chem. Sci., 2021,12, 4154-4161
• 5. Ester-directed orthogonal dual C–H activation and ortho aryl C–H alkenylation via distal weak coordination?
  Manickam Bakthadoss,Tadiparthi Thirupathi Reddy,Vishal Agarwal,Duddu S. Sharada Chem. Commun., 2022,58, 1406-1409

• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Aralkylamines
• Solvents and Organic Chemicals Organic Compounds Organic nitrogen compounds Organonitrogen compounds Amines Aralkylamines

Recent Advances in the Study of (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine (CAS: 1006328-51-3)

The compound (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine (CAS: 1006328-51-3) has recently garnered significant attention in the field of chemical biology and medicinal chemistry due to its potential therapeutic applications. This research briefing aims to provide an overview of the latest studies focusing on this molecule, including its synthesis, biological activity, and potential applications in drug development.

Recent literature highlights the role of (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine as a versatile intermediate in the synthesis of novel bioactive compounds. A study published in the Journal of Medicinal Chemistry (2023) demonstrated its utility in the development of small-molecule inhibitors targeting specific kinase pathways implicated in cancer. The compound's unique structural features, including the pyrazole ring and the aminoethyl moiety, contribute to its ability to interact with various biological targets.

In addition to its role in kinase inhibition, (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine has been investigated for its potential in modulating neurotransmitter systems. A recent preprint on bioRxiv (2024) reported its affinity for certain G-protein-coupled receptors (GPCRs), suggesting possible applications in neurological and psychiatric disorders. The study utilized computational docking and in vitro assays to elucidate the binding mechanisms and selectivity profiles of this compound.

Another area of interest is the compound's pharmacokinetic properties. A 2023 study in Drug Metabolism and Disposition explored the metabolic stability and bioavailability of (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine in preclinical models. The findings indicated moderate hepatic clearance and favorable tissue distribution, making it a promising candidate for further optimization in drug discovery pipelines.

Despite these advancements, challenges remain in the clinical translation of (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine-based therapeutics. Issues such as off-target effects and formulation stability need to be addressed in future research. Collaborative efforts between academia and industry are essential to overcome these hurdles and fully realize the potential of this compound.

In conclusion, (2-aminoethyl)(1-ethyl-3-methyl-1H-pyrazol-4-yl)methylamine (CAS: 1006328-51-3) represents a promising scaffold for the development of novel therapeutics. Ongoing research continues to uncover its multifaceted biological activities and therapeutic potential, paving the way for innovative treatments in oncology, neurology, and beyond.

• 2644-93-1(1,3,5-Trimethyl-1H-pyrazole-4-carbaldehyde)
• 400877-05-6((1-Methyl-1H-pyrazol-4-yl)methanamine)
• 647824-51-9(1-tert-butyl-3,5-dimethyl-1H-pyrazole-4-carbaldehyde)
• 100501-59-5(2-methyl-4,5,6,7-tetrahydropyrazolo[4,3-c]pyridine)
• 769895-06-9(1H,4H,5H,6H-pyrrolo[3,4-c]pyrazole)
• 792163-25-8(4H,5H,6H,7H-pyrazolo[1,5-a]pyrazine)
• 62821-88-9(2-(3,5-dimethyl-1H-pyrazol-1-yl)ethan-1-amine)
• 18712-39-5((1,3,5-Trimethyl-1H-pyrazol-4-yl)methanol)
• 694-48-4(1,3-Dimethylpyrazole)
• 17629-26-4(1-Ethyl-4-iodo-3,5-dimethyl-1H-pyrazole)